Core Insights - Minerva Neurosciences, Inc. has appointed Dr. Inderjit Kaul to its board of directors, who will also serve as a consultant for the clinical development of roluperidone [1][3] - The company successfully raised up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone, aimed at treating negative symptoms in schizophrenia [2] Company Developments - Dr. Kaul brings extensive experience in drug development, particularly in neurology and schizophrenia, which will be beneficial for the upcoming Phase 3 trial of roluperidone [3] - The company plans to enhance its board with members experienced in schizophrenia clinical trials to support the clinical operations for roluperidone [2] Clinical Context - Negative symptoms of schizophrenia, such as blunted affect and anhedonia, are significant unmet needs, with no FDA-approved treatments currently available for these symptoms [4][6] - Approximately 50% to 60% of individuals with schizophrenia experience primary negative symptoms, which do not respond to existing antipsychotic treatments [6]